TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00841672
Drug: Amlodipine 10 mg capsule
Normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Study: NCT00045812
Drug: SCH-58235
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01306851
Drug: Fibrin glue
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
Study: NCT03772340
Drug: Tradipitant
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00274040
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274040
Drug: Ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04423757
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
Study: NCT02372097
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 25mg, 50mg
Study: NCT02571491
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02571491
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
Study: NCT00075907
Drug: Efavirenz + 2 NRTIs
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00075907
Drug: Lopinavir/Ritonavir + 2 NRTIs
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00954811
Drug: 300IU rec-LH
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: luteal alternate doses
Study: NCT00954811
Drug: progesterone 600mg
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: luteal support
Study: NCT04434872
Drug: Fecal Microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00902772
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mg, oral dose
Study: NCT02884050
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antiepilepsy drug
Study: NCT01608750
Drug: Pantoprazol
Normalized name: Pantoprazol
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/day, oral, 28 days
Study: NCT01103180
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Study: NCT03364725
Drug: Glecaprevir-pibrentasvir
Normalized name: glecaprevir-pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
Study: NCT01668615
Drug: all-trans-retinoid acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg three times a day oral administration for 4 months
Study: NCT04403724
Drug: Bupivacaine-fentanyl-Morphine.
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
Study: NCT00116779
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
Study: NCT01268631
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
Study: NCT01268631
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
Study: NCT01545648
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection
Study: NCT00289848
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
Study: NCT03801135
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemocomplettan will be infused after plasma exchange procedure
Study: NCT01352572
Drug: antidepressant response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antidepressants administration for 6 weeks under therapeutic dose responders
Study: NCT04138901
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Study: NCT00401648
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03566199
Drug: Panobinostat Nanoparticle Formulation MTX110
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IT
Study: NCT03566199
Drug: Convection-Enhanced Delivery (CED)
Normalized name: CED
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo CED
Study: NCT00101270
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00101270
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01219816
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy + Epratuzumab
Study: NCT01219816
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine + Dexamethasone + Epratuzumab
Study: NCT03941808
Drug: Glisodin tablet
Normalized name: GliSODin
DrugBank: GliSODin (DB17013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Study: NCT00004008
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04526028
Drug: Fulvestrant Injectable Product
Normalized name: fulvestrant Injectable Product
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Study: NCT04526028
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
Study: NCT00086229
Drug: Chondroitin
Normalized name: Chondroitin
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00143442
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03426592
Drug: Vitamin D3, 10000 Intl Units Oral Capsule
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Study: NCT01211834
Drug: tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
Study: NCT02162134
Drug: Tab. Midazolam 7.5 mg
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study: NCT02162134
Drug: Inj. Midazolam 0.7mg/kg 45 min before surgery
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj . Midazolam 0.7 mg/kg given as premedication.
Study: NCT02162134
Drug: Inj. Propofol 2.5mg/kg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Study: NCT02162134
Drug: Inj. Atracurium 0.5 mg/kg
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It was given to induce muscle relaxation during anesthesia.
Study: NCT02162134
Drug: Sevoflurane 2.5 vol %
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Study: NCT02162134
Drug: Inj. Cefuroxime 1.5 g IV
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Study: NCT02927249
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03197480
Drug: Aflibercept Injection [Eylea]
Normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will receive 4 monthly intravitreal injections of aflibercept
Study: NCT00395629
Drug: Deferasirox (ICL670)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00987272
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00987272
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00987272
Drug: Olopatadine 0.2% Vehicle
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inactive ingredients used as placebo comparator
Study: NCT00987272
Drug: Olopatadine 0.1% Vehicle
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inactive ingredients used as placebo comparator
Study: NCT01294176
Drug: Lipoic Acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
Study: NCT03760276
Drug: Voriconazole Oral Product (Vfend®)
Normalized name: voriconazole Oral Product
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Study: NCT04460248
Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years.
Study: NCT04768530
Drug: Nitazoxanide hydrogel
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
Study: NCT00819104
Drug: Metoprolol XL 50mg + Amlodipine 5mg
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet,oral,OD,8 weeks
Study: NCT00819104
Drug: Metoprolol XL 25 mg + Amlodipine 2.5mg
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet,oral,OD,8 weeks
Study: NCT00819104
Drug: Metoprolol XL 50mg
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet,oral,OD,8 weeks
Study: NCT00819104
Drug: Metoprolol XL 25 mg
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet,oral,OD,8 weeks
Study: NCT00819104
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet,oral,OD,8 weeks
Study: NCT02120352
Drug: CAB Oral Tablets
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration.
Study: NCT02120352
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
Study: NCT02120352
Drug: RPV
Normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
Study: NCT01610206
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
Study: NCT01610206
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
Study: NCT03461185
Drug: EGFR-TK Inhibitor
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib
Study: NCT00093756
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00093756
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00093756
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00216515
Drug: galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01124045
Drug: Difluprednate ophthalmic emulsion, 0.05%
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ocular administration
Study: NCT00002977
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01094990
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
Study: NCT00830154
Drug: pagoclone
Normalized name: Pagoclone
DrugBank: Pagoclone (DB04903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg BID, 0.60 mg BID
Study: NCT01654185
Drug: AI plus Dimethyldiguanide
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AI 1 tablet per day Dimethyldiguanide 0.5 bid
Study: NCT03658785
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
Study: NCT03658785
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
Study: NCT03817853
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
Study: NCT03817853
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
Study: NCT03817853
Drug: Prednisone/Prednisolone/Methylprednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study: NCT03817853
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study: NCT03317652
Drug: Infusion of sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
Study: NCT00002977
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02549963
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00376246
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02840526
Drug: Propofol WZF
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol 2 mgkg-1intravenously (anesthesia induction)
Study: NCT02840526
Drug: Nimbex
Normalized name: Nimbex
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
Study: NCT02840526
Drug: Sevorane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
Study: NCT02840526
Drug: Bupivacaine WZF
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
Study: NCT00375960
Drug: V3381
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03222440
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study: NCT03527316
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg MDMA per os, single dose
Study: NCT03068234
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.